Kinetics of Antibodies Against Adalimumab Are Not Associated With Poor Outcomes in IBD

Abstract

and immunological prospective database, which included all patients followed up at the gastroenterology department. Eligible patients were defi ned as patients treated with adalimumab (ADA) at a maintenance dose (40 mg eow sc) without any concomitant treatment. Patients must also present, at the beginning of the kinetics study, undetectable trough level of… (More)
DOI: 10.1038/ajg.2015.79

Topics

3 Figures and Tables

Cite this paper

@article{Paul2015KineticsOA, title={Kinetics of Antibodies Against Adalimumab Are Not Associated With Poor Outcomes in IBD}, author={Steven M Paul and William Dronne and X Roblin}, journal={The American Journal of Gastroenterology}, year={2015}, volume={110}, pages={777-778} }